1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. CT/NG Testing Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of STIs worldwide
5.1.1.2. Growing awareness about the consequences of untreated infections
5.1.1.3. Rising need for point-of-care (POC) testing devices
5.1.2. Restraints
5.1.2.1. High costs associated with advanced diagnostic equipment
5.1.3. Opportunities
5.1.3.1. Government initiatives for promoting sexual health education
5.1.3.2. Integration of automation systems to enhance workflow efficiency
5.1.4. Challenges
5.1.4.1. Emergence of antibiotic-resistant strains by CT/NG testing
5.2. Market Segmentation Analysis
5.2.1. Product: Rapid adoption of instruments and analyzers for providing consistent results
5.2.2. Testing Type: Gaining popularity of PoC tests for CT/NG
5.2.3. Technology: Advancing Polymerase Chain Reaction (PCR)-based CT/NG testing for prioritizing accuracy over cost and speed
5.2.4. End User: Popularity of point-of-care testing for hospital and clinic settings
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. CT/NG Testing Market, by Product
6.1. Introduction
6.2. Assays & Kits
6.3. Instruments & Analyzers
7. CT/NG Testing Market, by Testing Type
7.1. Introduction
7.2. Lab Tests
7.3. PoC Tests
8. CT/NG Testing Market, by Technology
8.1. Introduction
8.2. Immunodiagnostics
8.3. Isothermal Nucleic Acid Amplification Technology
8.4. Polymerase Chain Reaction
9. CT/NG Testing Market, by End User
9.1. Introduction
9.2. Clinical Laboratories
9.3. Hospitals & Clinics
10. Americas CT/NG Testing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific CT/NG Testing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa CT/NG Testing Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Agreement, Collaboration, & Partnership
13.3.1.1. binx health Announces Strategic Supply Agreement with Afaxys to Expand Sexual Health Test Access to Thousands of Clinics Nationally
13.3.2. New Product Launch & Enhancement
13.3.2.1. Bio-Rad Launches Exact Diagnostics CT/NG, STI Run Controls
13.3.3. Award, Recognition, & Expansion
13.3.3.1. Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. Becton, Dickinson and Company
14.1.3. Binx Health, Inc.
14.1.4. Bio-Rad Laboratories, Inc.
14.1.5. Bioneer Corporation
14.1.6. Danaher Corporation
14.1.7. ELITech Group SAS
14.1.8. F. Hoffmann-La Roche Ltd.
14.1.9. Geneproof A.S.
14.1.10. Genetic Signatures Ltd.
14.1.11. Goffin Molecular Technologies B.V.
14.1.12. Hologic, Inc.
14.1.13. Meridian Bioscience Inc.
14.1.14. Microbiologics, Inc.
14.1.15. Molbio Diagnostics Pvt. Ltd.
14.1.16. Operon S.A.
14.1.17. PerkinElmer Inc.
14.1.18. QIAGEN N.V.
14.1.19. Sansure Biotech Inc.
14.1.20. Seegene, Inc.
14.1.21. Siemens Healthineers AG
14.1.22. Thermo Fisher Scientific Inc.
14.1.23. Tianlong Technology Co., Ltd.
14.1.24. Vircell S.L.
14.1.25. Visby Medical, Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
